These results support that the use of palbociclib alone has limited activity in HNSCC, likely because of the rapid acquisition of adaptive resistance through a positive feedback loop resulting in increased CCNE1 expression, which can be prevented by the concomitant mTOR pathway blockade (Fig. 5). The gene discussed is MTOR; the disease is head and neck squamous cell carcinoma.